United Therapeutics Corporation (NASDAQ:UTHR) traded at $115 at last check on Friday, Oct 16, making an upward move of 1.74% on its previous day’s price.
Looking at the stock we see that its previous close was $113.03 and the beta (5Y monthly) reads 0.66 with the day’s price range being $112.27 – 115.69. The company has a 12-month trailing PE ratio of 11.8. In terms of its 52-week price range, UTHR has a high of $127.79 and a low of $75.58. The company’s stock has gained about 7.81% over that past 30 days.
United has a market cap of $5.15 Billion and is expected to release its quarterly earnings report on Oct 28, 2020- Nov 02, 2020. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the UTHR stock to lose ahead of the earnings release. Estimates by analysts give the company expected earnings per share (EPS) of $2.78, with the EPS growth for the year raised at $11.39 for 2020 and $10.8 for next year. These figures represent -5.77% and at -0.05% growth in EPS for the two years respectively.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $356.95 Million, with a low of $332.83 Million and a high of $386.05 Million. The median projection represents growth adding up to -11.1% compared to sales earnings for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecasts for 2020 are expected to hit $1.42 Billion, or -1.7% down from figures reported last year.
There have been 1 upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the UTHR stock, short term indicators assign the stock an average of 50% Sell, while medium term indicators assign it an average of 50% Sell. Long term indicators on average place the stock in the category of 100% Buy.
Based on estimates by 11 analysts where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 2 have rated the United Therapeutics Corporation (UTHR) stock as a Hold, while 7 rate it as a Buy. None analysts rate it as outperform while 1 of them rated it as underperform, whereas 1 suggests the stock as a Sell. The stock has an overall rating of Overweight and investors could take advantage and scoop up stock of the company.
Looking further, we note that the PEG ratio for the UTHR stock currently stands at 0, and the current price level is 10.81% off its SMA20 and 8.76% from its 50-day simple moving average. The RSI (14) is pointing at 71.15 while the volatility over the past week is 3.5% and drops to 3% over the past one month. The beta value is 0.66, while the average true range (ATR) is currently pointing at 3.1. The average price target for the stock over the next 12 months is $144.4, with the estimates having a low of $95 and a high of $247. These price ends are -17.39% and +114.78% off the current price level respectively, although investors could be excited at the prospect of a +23.04% if the UTHR share price touches on the median price of $141.5.
Let’s briefly compare United (UTHR) stock to its peers. We find that today’s price change of +1.74% and +40.81% over the past 12 months for UTHR betters that of Zoetis Inc Cl A (ZTS), which has seen its stock price rise 0.34% in the latest trading session and is +27.31% over the last one year. Another of its peers Takeda Pharmaceutical CO Ltd (TAK) has dropped -1.3% today, but is -4.91% down over the past year, while Catalent Inc (CTLT) is also up 1.74% yet its price remains in the green at 40.81% over the same period. Zoetis has a P/E ratio of 48.37 compared to United’s 11.8 and Takeda’s 20.54. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at 0.01% and 0.39%, respectively, in early deals.
Coming back to United Therapeutics Corporation (NASDAQ:UTHR), we note that the average 3-month trading volume was 302.32 Million, while that of the preceding 10-day period stands at 361.14 Million. Current shares outstanding are 44.41 Million.
According to data from Thomson Reuters, insiders hold 1.77% of the company’s shares while institutions hold 97.53%. The data shows that short shares as of September 29, 2020, stood at 2.04 Million at a short ratio of 6.94. This represents a 4.58% Short interest in Shares outstanding on September 29, 2020. Shares short rose in September from the previous month at 1.84 Million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock +30.56% up in year-to-date price movement.